ODYSSEY PHARMACEUTICALS, INC. – Trademark Portfolio
Entity Type: 03
ODYSSEY PHARMACEUTICALS, INC. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include VOSPIRE, CYCLOSET, and VOSPIRE ER. The owner is based in FLORHAM PARK, NJ.
200 PARK AVENUE
FLORHAM PARK, NJ 07932
Showing of trademarks Trademarks
Trademark Classifications
ODYSSEY PHARMACEUTICALS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does ODYSSEY PHARMACEUTICALS, INC. have?
ODYSSEY PHARMACEUTICALS, INC. has 23 U.S. trademarks filed with the USPTO. Of these, 3 registered, 11 abandoned, 9 cancelled.
What trademark classes does ODYSSEY PHARMACEUTICALS, INC. file in?
ODYSSEY PHARMACEUTICALS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ODYSSEY PHARMACEUTICALS, INC.'s most well-known trademarks?
ODYSSEY PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as VOSPIRE, CYCLOSET, and VOSPIRE ER. These are among 3 currently registered trademarks in the portfolio.
What is ODYSSEY PHARMACEUTICALS, INC.'s trademark registration success rate?
ODYSSEY PHARMACEUTICALS, INC. has a 13% trademark registration rate, with 3 out of 23 resolved applications resulting in successful registration. Currently, 0 applications are pending review.